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Abstract: Thiazoles, oxazole and their corresponding reduced derivatives, thiazolines and 
oxazolines, are found in marine sources exhibiting significant biological activities. The 
isolation,  synthetic,  and  biological  studies  of these natural  products, covering  literature 
from January 2007 to June 2010, are summarized. 
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1. Introduction  
The role of natural products in drug discovery has undergone many changes over the past two 
decades, from a decline in participation by pharmaceutical companies in the 1990s, to a renaissance in 
recent years. In addition, the expectations from combinatorial libraries in drug screening have not been 
fulfilled and more than 60% of prescription drugs are of natural product origin. As a consequence, the 
natural  product-inspired  drug  discovery  and  development  has  received  renewed  attention  in  
recent years.
 
A large number of natural products, in particular from the marine environment, contain thiazole, 
oxazole, thiazolines or oxazolines heterocycles. In many cases, promising anti-tumor, antibacterial, 
anti-viral,  anti-malaria  and  anthelmintic  activities  have  been  identified  for  these  compounds.  This 
review focusses on the isolation and structural determination, biological activities and synthetic studies 
of these marine products covering literature from January 2007 to June 2010. 
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2. New Thiazoles Isolated from Marine Sources 
The known algaecide bacillamide A (1) and two new analogues, bacillamides B (2) and C (3), 
Figure 1, were isolated from Bacillus endophyticus obtained from a Bahamian hypersaline microbial 
mat [1]. The detection of these metabolites containing tryptamide thiazole motif, was performed using 
HPLC-UV-MS  bioassay  technique.  Due  to  a  lack  of  sufficient  material  and  the  appropriate  test 
organisms,  bacillamides  B  and  C  were  not  tested  for  algicidal  activity.  None  of  the  purified 
bacillamides demonstrated antibiotic activity against target isolates of hypersaline pond Bacillus sp. at 
concentrations less than 500 μM.  
A related compound, neobacillamide A (4), Figure 1, together with bacillamide C, was isolated 
from  the  bacterium  Bacillus  vallismortis  C89  associated  with  the  sponge  Dysidea  avara  [2]. 
Neobacillamide A represents the first example of a thiazole-carboxamide bearing a 2-phenylethylamine 
moiety. Both compounds, Neobacillamide and Bacillamide C were inactive as cytotoxic against HL60 
human leukemia cells and A549 human lung cancer cells. 
Figure 1. Structures of bacillamide A, B and C and neobacillamide A. 
 
A  thiopeptide  antibiotic,  urukthapelstatin  A  (5),  Figure  2,  was  isolated  from  a  culture  of 
Thermoactinomycetaceae  bacterium  Mechercharimyces  asporophorigenens  YM11-542  [3].  Its 
structure was determined by spectroscopic methods and chemical degradation, and confirmed by X-ray 
crystallographic  analysis.  It  is  related  to  24  membered  cyclic  compounds  mechercharstatin  and 
telomestatin. Urukthapelstatin A inhibited the growth of human lung cancer A549 cells with an IC50 
value of 12 nM and also showed potent cytotoxic activity against a human cancer cell line panel.  
Figure 2. Structures of urukthapelstatin A. 
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Two new cyclic hexapeptides, venturamides A (6) and B (7), Figure 3, were isolated from the 
anamanian  marine  cyanobacterium  Oscillatoria  sp.  [4].  Venturamide  A  and  B  showed  in  vitro 
antimalarial activity against Plasmodium falciparum (8.2 and 5.6 M respectively), with only mild 
cytotoxicity to mammalian Vero cells (86 and 56 M respectively). They exhibited only mild activity 
against Trypanasoma cruzi and Leishmania donovani. 
Figure 3. Structures of venturamide A and B. 
 
Four new modified hexacyclopeptides, aerucyclamides A (8), B (9), C (10) and D (11), Figure 4, 
were isolated from the toxic freshwater cyanobacterium Microcystis aeruginosa PCC 7806 [5,6]. These 
compounds encompass hexameric cyclopeptides alternating in hydrophobic aminoacids and oxazoline, 
thiazoline,  thiazole  or  oxazole  heterocycles  derived  from  hydrophilic  aminoacids  (Ser,  Thr,  Cys). 
Aerucyclamide B displayed a submicromolar (0.7 M) IC50 value against the chloroquine-resistant 
strain K1 of P. falciparum. In addition, this compound displays a large selectivity for the parasite with 
respect to the L6 rat myoblast cell line. Aerucyclamides A, C y D displayed low micromolar activity 
against P. falciparum. The most active compound against T. brucei rhodesiense, is aerucyclamide C 
(10), albeit with moderate activity. 
Figure 4. Structures of aerucyclamides A, B, C and D. 
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A  new  hexapeptide,  Hexamollamide  (12),  Figure  5,  was  isolated  from  an  Okinawan  ascidian 
Didemnum molle [7]. The relative stereostructure was confirmed by X-ray crystallographic analysis. 
Hexamollamide contains a thiazoline ring and a threonine amino acid, which is modified by attachment 
to  a  dimethylallyl  ether.  It  is  structurally  similar  to  patellin  2  isolated  from  L.  patella  [8,9]. 
Hexamollamide showed moderate cytotoxicity against HeLa S3 cells, with an IC50 value of 17 g/mL. 
Figure 5. Structure of hexamollamide. 
 
Two  new  cyclic  hexapeptides,  mollamides  B  (13)  and  C  (14),  Figure  6,  were  isolated  from 
Didemnum molle collected from Manado Bay [10]. They contain threonine or serine amino acids, 
modified by attachment to a dimethylallyl ether. The relative configuration of mollamide B at the 
thiazoline moiety was determined using molecular modeling coupled with NMR-derived restraints. 
Their  absolute  configuration  was  determined  using Marfey’s method. Mollamide B (13) exhibited 
moderate antimalarial activity against Plasmodium falciparum (D6 clone and W2 clone), with IC50 
values  of  2.0  and  2.1  μg/mL,  respectively.  Mollamide  B  also  exhibited  marginal  activity  against 
Leishmania donovani, with IC50 and IC90 values of 18 and 35 μg/mL and cytotoxicity against several 
cancer cell lines. It showed neither antimicrobial nor anti-inflammatory activities. Mollamide C has not 
shown antiinflamatory activity and it was not considered to be solid tumor selective. 
Figure 6. Structures of mollamide B and C. 
 
In 2008, a new metabolite with novel chemical scaffold and nanomolar antiproliferative activity, 
largazole (15), Figure 7, was  isolated from  a sample of a cyanobacterium of the genus Symploca 
collected from Key Largo, Florida Keys, U.S. [11]. It potently inhibited the growth of highly invasive Mar. Drugs 2010, 8                                                  
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transformed  human  mammary  epithelial  cells  (MDA-MB-231)  (GI50  =  7.7  nM).  In  contrast, 
nontransformed murine mammary epithelial cells (NMuMG) were less susceptible (GI50 = 122 nM). 
The  authors  suggested  that  cancer  cells  are  preferentially  targeted  by  largazole.  It  possesses  a 
combination  of  unusual  structural  features,  including  a  substituted  4-methylthiazoline  fused  to  a 
thiazole,  a  thioester  moiety  that  has  not  been  reported  in  metabolites  from  cyanobacteria  and  the 
unprecedented in marine natural products 3-hydroxy-7-mercaptohept-4-enoic acid unit.  
Figure 7. Structure of largazole. 
 
From  an  environmental  assemblage  of  the  marine  cyanobacteria  Lyngbya  majuscula  and 
Phormidium gracile collected in Papua New Guinea, a novel bioactive cyclic depsipeptide, hoiamide A 
(16),  Figure  8,  was  isolated  [12].  The  structure  was  then  corrected  by  the authors in  an erratum, 
showing R configuration at C24 (instead of the S configuration pictured in the original paper) [13]. 
This metabolite possesses an unusual structure derived from a mixed peptide-polyketide biogenetic 
origin,  and  includes  three  fragments:  a  triheterocycle  bearing  two  methylated  thiazolines  and  one 
thiazol, a peptide and an oxygenated and methylated C15-polyketide. Hoiamide A exhibited modest 
cytotoxicity to cancer cells, but potently inhibited [
3H]batrachotoxin binding to voltage-gated sodium 
channels  (IC50  =  92.8  nM)  and  activated  sodium  influx  (EC50  =  2.31  μM)  in  mouse 
neocortical neurons.  
Figure 8. Structure of hoiamide A. 
 
Eight  novel  thiazole  and  oxazole  containing  cyclic  peptides,  microcyclamides,  GL616  (17), 
GL582 (18), GL614A (19), GL614B (20), GL546A (21), GL546B (22), GL628 (23), GL614C (24), 
Figure 9, were isolated from the hydrophilic extract of a Mycrocystis sp. water-bloom collected in 
Gelbea reservoir, Valley of Armagedon, Israel [14]. It is the first example where acidic and modified 
aminoacids are incorporated in this group of ribosomally biosynthesized metabolites. The compounds Mar. Drugs 2010, 8                                                  
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were  assayed  against  one  solid  tumor  (A549-lung)  and  one  leukemis  (Molt-4)  cell  lines. 
Microcyclamides GL582 (18) displayed weak cytotoxicity (20% grow inhibition) against Molt-4 cell 
line at 10 M/mL. 
Figure 9. Structures of microcyclamides. 
 
3. Thiazolines Isolated from Marine Sources 
A collection of the cyanobacterium Lyngbya confervoides off Grassy Key in Florida,U.S., yielded 
grassypeptolide  (25),  Figure  10,  a  31-membered  macrocyclic  depsipeptide  with  unusually  high 
D-amino acid content, two thiazolines, and one -amino acid [15]. The structure was confirmed by 
X-ray  crystallography.  The  antiproliferative  activity  was  evaluated  in  four  cell  lines  derived  from 
human  osteosarcoma  (U2OS),  cervical  carcinoma  (HeLa),  colorectal  adenocarcinoma  (HT29),  and 
neuroblastoma (IMR-32). Grassypeptolide showed moderate broad-spectrum activity with IC50 values 
of 2.2, 1.0, 1.5, and 4.2 M, respectively. Mar. Drugs 2010, 8                                                  
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Figure 10. Structure of grassypeptolide. 
 
A  new  thiazoline  metabolite,  bisebromoamide  (26),  Figure  11,  was  isolated  from  the  marine 
cyanobacterium  Lyngbya  sp.  [16].  Its  planar  structure  was  determined  by  1D  and  2D  NMR 
spectroscopy. The absolute stereostructure was determined by chemical degradation followed by chiral 
HPLC analysis. It contains a significant number of D-amino acids and N-methylated amino acids along 
with several other modified amino acid residues. Bisebromoamide exhibited antiproliferative activity at 
nanomolar levels and potent kinase inhibition.  
Figure 11. Proposed structure in the isolation report of bisebromoamide. 
 
4. Synthesis of Thiazoles of Marine Origin and Analogues 
The synthesis of the C1-N15 fragment of the originally proposed scleritodermin A (27), Figure 12, 
has been reported in good overall yield through a short and stereocontrolled sequence [17]. Highlights 
of the route include the synthesis of the novel ACT fragment (28) and the formation of the α-ketoamide 
linkage by the use of a highly activated α,β-ketonitrile. 
In 2008, the first total synthesis of the originally proposed scleritodermin A (27) along with two 
isomers (29) and (30) were achieved [18]. The application of a transamination reaction was used for 
the formation of α-ketoamide. The authors reported that 
1H and 
13C NMR spectra of molecule 27 did 
not match those reported for natural scleritodermin. In contrast, the spectra of compound 29 and those 
reported  for  the  isolated  marine  product  were  identical.  Thus,  compound  29 was  proposed as  the 
revised structure of scleritodermin A.  Mar. Drugs 2010, 8                                                  
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Figure 12. Retrosynthetic analysis of scleritodermin A. 
 
Recently, the synthesis of key fragments and open analogs of scleritodermin A and their biological 
evaluation as cytotoxic and anthelmintic were reported. Open and simplified analogs (31), Figure 13, 
were obtained in very good yield using a convergent strategy [19]. The compound with the highest 
antihelminthic activity is the open analog of 27 (LC50 = 9.6 M). The presence, in some obtained 
compounds, of ,-ketoamide function improves the cytotoxic activity on HCT-15 cells. 
Figure 13. Synthesized analogs of scleritodermin A. 
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Pattellamide A (32), Figure 14, was synthesized from thiazole 33 and protected aminoacids using 
Burgess reagent to obtain the oxazolines rings. Macrocyclization was performed using PyBOP, DMAP, 
DIEA in CH2Cl2/DMF [20]. 
Figure 14. Synthetic route to patellamide A. 
 
The first total synthesis of Largazole (15), Figure 7, was reported four months after the publication 
of  its  isolation  [21].  The  synthesis  (eight  steps,  19%  overall  yield),  involved  a  macrocyclization 
reaction  for  formation  of  the  strained  16-membered  depsipeptide  core  followed  by  an  olefin 
cross-metathesis  reaction  for  installation  of  the  thioester,  Figure  15.  The  biological  evaluation  of 
largazole and key analogues, suggested that histone deacetylases (HDACs) are molecular targets of 
largazole. The authors concluded that the cell growth inhibition is a functional consequence of I HDAC 
inhibition. In addition, structure-activity relationship (SAR) studies revealed that the thiol group is 
indispensable for both activities.  
Figure 15. Retrosynthetic analysis of the first total synthetis of largazole. 
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During  2008  seven  more  syntheses  of  largazole  were  reported  [22–28].
  Some  of  the  used 
methodologies  differ  in  the  formation  of  the  macrocycle  or  in  the  precursor  of  the  3-hydroxy-7-
mercaptohept-4-enoic acid. In addition, some structure activity relationships studies were performed. It 
was demonstrated that largazole is a pro-drug that is activated by removal of the octanoyl residue from 
the 3-hydroxy-7-mercaptohept-4-enoic acid moiety to generate the active metabolite 34, Figure 16, 
which is an extraordinarily potent Class I histone deacetylase inhibitor (Ki = 0.07 nM) [22]. 
Figure 16. Active metabolite of largazole. 
 
During  2009,  six  reports  related  to  the  synthesis  of  largazole  and/or  analogs  were  published  
[29–34]. A significant increase in potency with a pyridine substitution of the thiazole was reported. In 
addition, it was demonstrated that the methyl substituent of the thiazoline ring is nonessential for the 
dramatic  potency  of  the  natural  product.  In  contrast,  substitution  of  the  thiazoline  by  thiazol, 
diminishes the activity [30]. 
Recently, new analogs of largazole were synthesized [35,36]. Structure-activity relationship studies 
suggested that the geometry of the alkene in the side chain is critical. While the largazole’s analogues 
with  trans-alkene  are  potent  for  the  antiproliferative  effect,  those  with  cis-alkene  are  completely 
inactive. In addition, replacement of valine by tyrosine increased selectivity toward human cancer cells 
over human normal cells more than 100-fold [35]. 
Starting  from  D-alanine,  bacillamide  C  (3),  was  obtained  in  22%  overall  yield  [37].  The  key 
intermediate, thiazole 35, Figure 17, was synthesized using Hantzsch reaction. 
Figure 17. Thiazole precursor of bacillamide C. 
 
A thiazole Ugi multicomponent reaction and an aminolisis reaction were used to obtain racemic 
Bacillamide  C,  Figure  18  [38].  Additionally,  several  analogs  of  this  natural  product  and  a  fluoro 
derivative of neobacillamide (4), Figure 1, were synthesized.  Mar. Drugs 2010, 8                                                  
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Figure 18. Synthesis of bacillamide C. 
 
Recently,  the  enantioselective  total  synthesis  of  trichloroleucine-derived  marine  natural  product 
neodysidenin (36), Figure 19, was accomplished. The strategy involves a direct ruthenium-catalyzed 
radical chloroalkylation capitalizing on the valence tautomerism of titanium enolates [39]. 
Figure 19. Retrosynthetic analysis of neodysidenin. 
 
5. Synthesis of Thiazolines of Marine Origin and Analogues 
The cytotoxic thiazoline, apratoxin A (37), Figure 20, was synthesized in 18 steps and 18% overall 
yield. In addition, an oxazoline analogue (38) and 34-epiapratoxin A (39) were obtained [40]. The 
synthetic  strategy  to  obtain  apratoxin  A  involves  the  preparation  of  fragment  40  through  a 
stereoselective  route  based  in  three  asymmetric  reactions.  Thiazoline  formation  was  successfully 
accomplished from a Cys amide using Ph3PO/Tf2O and macrolactamization was performed between 
N-methylisoleucine and proline residues using HATU.  
Recently, the first total synthesis and a revised configurational assignment of bisebromoamide were 
reported [41]. The authors synthesized the originally proposed structure (26), Figure 11, but, neither 
NMR spectra nor optical rotation for the obtained compound were identical with those of the natural 
product. The authors elected to synthesize the epimer with R-configuration of the stereogenic center at 
the thiazoline ring of the proposed structure (41), Figure 21, from different fragments as is shown in 
the retrosynthetic analysis. The spectral data and optical rotation for 41 were identical to those of the 
natural product leading to a revision of the reported stereochemistry of bisebromoamide. 
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Figure 20. Apratoxin A analogs and retrosynthetic analysis of apratoxin A. 
 
Figure 21. Retrosynthetic analysis of bisebromoamide. 
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6. New Oxazoles Isolated from Marine Sources 
A new marine-derived macrolide designated as neopeltolide (42), Figure 22, was isolated from a 
deep-water sponge of the family Neopeltidae. Its structure was elucidated on the basis of spectroscopic 
data interpretation. Neopeltolide is a potent inhibitor of the in vitro proliferation of the A-549 human 
lung adenocarcinoma, the NCI-ADR-RES human ovarian sarcoma, and the P388 murine leukemia cell 
lines, with IC50 of 1.2, 5.1, and 0.56 nM, respectively. 42 also inhibited the growth of the fungal 
pathogen Candida albicans with a minimum inhibitory concentration of 0.62 μg/mL [42]. 
Figure 22. Structure of neopeltolide. 
 
Ariakemicins A (43) and B (44), Figure 23, unusual linear hybrid polyketide-nonribosomal peptide 
antibiotics,  were  discovered  from  the  fermentation  extract  of  the  marine  gliding  bacterium 
Rapidithrix sp. [43].  These  metabolites  were  positional  isomers  with  regard  to  a  double  bond  and 
chromatographically  inseparable,  rendering  the  structure  study  on  a  mixture  basis.  The  antibiotics 
selectively inhibited the growth of Gram-positive bacteria. 
Figure 23. Structure of ariakemicins A and B. 
 
Bioassay-guided  fractionation  of  extract  of  the  sponge  Dorypleres  splendens  has  led  to  the 
discovery of a new natural source of bengazole A (45), B (46), and E (47), Figure 24, together with 
bengamide A. It had been thought that these compounds were confined to Jaspis species. This is the 
first  time  that  bengazoles  were  isolated  from  another  genus.  Those  compounds  showed  growth 
inhibitory activity to seven murine and human cancer cell lines [44]. 
Figure 24. Structure of bengazoles A, B and E. 
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An  oxazole  lipodepsipeptide, taumycins  A (49), Figure 25, were isolated from  the Madagascar 
sponge Fascaplysinopsis sp. with other closely related no oxazole containing metabolite taumycine B. 
The two compounds have the same 12-membered oxodepsipeptide ring system in common. Both were 
toxic to brine shrimp larvae, and taumycin A (1 μM), but not taumycin B, inhibited growth of the 
human  UT-7  leukemic  cell  line.  The  structure  of  the  two  compounds,  likely  to  be  derived  from 
microorganisms, was established by MS and 1D and 2D NMR data [45]. 
Figure 25. Structure of taumycin A. 
 
A novel oxazole macrolide, salarin C (50), Figure 26, was isolated from the Madagascar sponge 
Fascaplysinopsis sp. The structure of the compound was elucidated by interpretation of MS and 1D 
and  2D  NMR  spectra.  Salarin  C  (50)  is  closely  related  to  salarin  A  and  is  considered  to  be  the 
precursor of salarins A and B. Air oxidation was found to transform 50 to salarin A. 50 was found to 
inhibit cell proliferation of human leukeamic cell lines UT-7 and K562, and the murine pro-B cell line 
Ba/F3 at concentrations of 0.0005–0.5 µg/mL [46]. 
Figure 26. Structure of salarins C, F and I. 
 
Recently, seven new nitrogenous macrolides, designated salarins D-J, closely related to salarins 
A-C, were isolated from the same source. Salarin F (51) and I (52), Figure 26, have the same oxazole 
macrolide that 50. All compounds were evaluated for their cytotoxicity against K562 and UT-7 human 
leukemia  cells.  While  salarins  D,  E,  H,  and  J  displayed  dose-  and  time-dependent  inhibition  of 
proliferation, 51 and 52 were not active in these assays [47]. 
Two  new  trisoxazole  macrolides,  9-O-desmethylkabiramide  B  (53)  and 
33-methyltetrahydrohalichondramide  (54),  Figure  27,  were  isolated  in  submicromolar  amounts 
together with two new thiazole-containing cyclic peptides from a single specimen of Hexabranchus 
sanguineus,  a  nudibranch  from  the  Indo-Pacific.  The  structure  elucidation  of  these  very  minor 
metabolites was preformed using a 1 mm 
1H NMR high-temperature superconducting microcryoprobe 
with unmatched sensitivity [48]. Mar. Drugs 2010, 8                                                  
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Figure 27. Structure of trisoxazole macrolides. 
 
Three new macrocyclic peptides, diazonamides C–E (55–57), Figure 28, were isolated together with 
the  previously  reported  diazonamides  A  and  B  from  samples  of  the  marine  ascidian  Diazona  sp. 
collected in Indonesia. The cytotoxic activity of the new compounds and diazonamide A was evaluated 
against a panel of three human tumor cell lines, including lung (A549), colon (HT29), and breast 
(MDA-MB-231). Moderate cytotoxicity with GI50 values in the micromolar range was found for the 
new compounds; whereas the potent activity previously reported for diazonamide A was confirmed 
with values in the low nanomolar range [49]. 
Figure 28. Structure of diazonamides. 
 
Enigmazole  A  (58),  a  novel  phosphate-containing  macrolide,  was  isolated  from  a  Papua  New 
Guinea collection of the marine sponge Cinachyrella enigmatica [50]. Compound 58 is comprised of 
an  18-membered  phosphomacrolide  that  contains  an  embedded  exomethylene-substituted 
tetrahydropyran ring and an acyclic portion that spans an oxazole moiety. Two additional analogues, 
15-O-methylenigmazole  A  and  13-hydroxy-15-O-methylenigmazole  A,  were  also  isolated.  The 
enigmazoles  are  the  first  phosphomacrolides  from  a  marine  source  and  58  exhibited  significant 
cytotoxicity in the NCI 60-cell line antitumor screen, with a mean GI50 of 1.7 μΜ. 
Figure 29. Structure of enigmazole A. 
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7. Synthesis of Oxazoles of Marine Origin and Analogues 
The  relative  stereochemistry  of  the  metabolite  (+)-neopeltolide  (42),  Figure  22,  was  originally 
proposed  based  on  1D  and  2D  NOESY  spectra,  which  ultimately  led  to  the  incorrect  structural 
assignment.  The  enantioselective  total  synthesis,  with  reassigned  stereochemical  and  absolute 
configuration  for  neopeltolide  (59),  Figure  30,  and  their  diastereomers  has  been  reported  almost 
simultaneously by Panek
 [51] and Scheidt [52]. 
Figure 30. Revised structure of neopeltolide. 
 
Retrosynthetic strategy by Panek, Figure 31, began with disconnection of the C19–C20 double bond 
to reveal the macrolide 60 and the oxazole side chain 61. Synthetic highlights of this route include a 
modified  Evans-Tishchenko  reduction  to  introduce  the  C11  stereocenter,  [4  +  2]  annulation  to 
construct  the  pyran  system,  and  a  Still-Gennari  olefination  to  install  the  oxazole  side  chain. 
Macrocyclization was performed through Yamaguchi esterification of the seco acid intermediate to 
form macrolide 60 in 44% yield. The longest linear sequence required 19 steps with an overall yield 
of 1.3%. 
Figure 31. Retrosynthetic analysis of neopeltolide by Panek. 
 
Scheidt  and  co-workers  performed  a  macrocyclization  of  the  linear  precursor  62,  Figure  32, 
constructed from dioxinone acid 63 and alcohol 64. In this key step, scandium-(III) triflate promoted 
the  macrocyclization  of  62  in  a  Prins  type  transformation.  The  synthetic  neopeltolide  inhibited 
proliferation  of  the  murine  leukemia  line  P388  with  an  IC50  of  0.6  nM  and  the  human  breast 
adenocarcinoma line MCF-7 with an IC50 value of 2.2 nM. Validating the revised structure as the 
correct one; diastereomer which corresponded to the originally proposed structure, was approximately 
100-fold less active in both cell lines [53]. Mar. Drugs 2010, 8                                                  
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Figure 32. Retrosynthetic analysis of neopeltolide by Scheidt group.  
 
Five  total  syntheses  of  59  have  been  reported  in  2008  [54–58]  and  they  were  reviewed  by 
Sasaki [59]. Since then, another four total syntheses were reported [60–64]. 
The  first  total  synthesis  of  the  cytotoxic  marine  macrolide  enigmazole  A  (58),  Figure  29,  was 
completed in 22 steps (longest linear sequence). The sensitive, densely functionalized 2,4-disubstituted 
oxazole fragment (64), Figure 33, was constructed using a Negishi-type coupling of an oxazol-2-ylzinc 
reagent formed directly from the parent ethyl 2-iodooxazole-4-carboxylate by zinc insertion. Other key 
steps include a hetero-Diels-Alder cycloaddition to form the central embedded pyran ring, a Wittig 
reaction to unite the hemispheres, and a ring size-selective Keck macrolactonization [65]. 
Figure 33. Retrosynthetic analysis of enigmazole A by Molinski . 
 
Figure 34. Structure of ulapualide A and their retrosynthetic analysis. 
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Stereochemistry of (-)-ulapualide A (65), Figure 34, was revised by X-ray analysis of its complex 
with  the protein actin. A new total  synthesis  of  65 was  reported, the first to yield a product that 
corresponds  with  the  natural  product.  The  synthesis  involved  the  macrolactamization  of  the 
intermediate 66, followed by elaboration of the central oxazole ring in 65 as a late step in the overall 
synthesis [66,67]. 
An  enantioselective,  convergent,  total  synthesis  of  the  antiviral  marine  natural  product  
(-)-hennoxazole A (67), Figure 35, was completed in 17 steps, longest linear sequence, from serine 
methyl  ester  and  in  nine  steps  from  an  achiral  bis-oxazole  intermediate.  Elaboration  of  a 
thiazolidinethione allowed for rapid assembly of the pyran-based ring system. Key late-stage coupling 
was effected by deprotonation of the bisoxazole methyl group, followed by alkylation with an allylic 
bromide side chain segment [68,69].  
Figure 35. Structure of hennoxazole A. 
 
Siphonazoles A (68) and B (69), Figure 36, are structurally novel natural products isolated from a 
Herpetosiphon species [70]. They are the first, and so far the only, naturally occurring substances 
known that incorporate oxazole subunits connected by a two-carbon tether. 
The first synthesis of a siphonazole was performed by Moody and Linder [71,72]. Key aspects of 
this work are the assembly of oxazole units via the reaction of rhodium carbenes with an amide or a 
nitrile,  and  the  construction  of  the  central  (2-oxazolyl)methyl  ketone  motif  by  acylation  of  an 
organozinc agent derived from 4-carbomethoxy-2-iodomethyl-5-methyloxazole. 
Other synthesis of siphonazoles was performed by Ciufoloni and co-workers involving the iterative 
use of a conjunctive oxazole building block that acts as a carrier of synthon 70, Figure 36. Synthetic 
siphonazoles  were  devoid  of  antimicrobial  activity,  but  they  showed  appreciable  and  selective 
cytotoxicity against human breast carcinoma HTB-129 (IC50 of 20 μg/mL) and acute T-cell leukemia 
TIB-152 (IC50 value equal to 16 μg/mL), with 68 being significantly more active than 69 [73]. 
Figure 36. Structure of siphonazoles A–B and their retrosynthetic analysis by Ciufoloni group. 
 
The  bengazoles  are  a  family  of  metabolites  isolated  from  a  Jaspis  sponge  that  display  potent 
antifungal and anthelmintic activity, and have a unique structure containing two oxazole rings flanking Mar. Drugs 2010, 8                                                  
 
 
2773 
a  single  carbon  atom.  Three  new  total  synthesis  of  bengazoles  [74–76]  and  analogs  [77–79]  
were reported.  
The marine alkaloid almazole C (71), Figure 37, isolated from the red seaweed Haraldiophylum sp. 
was synthesized in four steps. The key step, construction of the central 2,5-disubstituted oxazole ring, 
was based on the aza-Wittig reaction of the iminophosphorane derived from the α-azidoacetyl indole 
and (S)-N-phthaloylphenylalanyl chloride [80]. 
The structure of Almazole D (72), Figure 37, antibacterial metabolite isolated from a red seaweed 
from the Dakar coast [81], was revised by Horne and co-workers to 73. Synthesis of 73 was performed 
by  coupling  the  oxotryptophan  methyl  ester  with  N,N-dimethyl-L-phenylalanine  and  subsequent 
treatment with POCl3 [82]. 
Figure 37. Structure of almazoles. 
 
The complex structure of phorboxazoles and their unique biological activity is a driving force for 
continued  interest  from  the  synthetic  community.  The  phorboxazoles  are  among  the  most  potent 
discovered cytostatic agents, exhibiting a mean GI50 < 1.58 ×  10
−9 M against the NCI panel of 60 
tumor cell lines. Phorboxazole B (74), Figure 38, was prepared in 55 steps (longest linear sequence 28 
steps) using a stereoselective hetero-Diels-Alder reaction to construct the key C33–C39 segment. The 
stereoselective  hetero-Diels-Alder  reaction  of  (R)-2,3-dibenzyloxypropanal  and  the  Brassard  diene 
EtO(Me3SiO)C:CHC(OMe):CH2  in  presence  of  Eu(fod)3  provided  dihydropyranone I, enabling the 
synthesis of the C18–C46 fragment of phorboxazole B. Coupling of the C18–C46 fragment with a 
suitable  C3–C17  partner,  followed  by  the  late-stage  formation  of  the  C16–C18  oxazole  unit  and 
stereoselective macrocyclization and deprotection, rendered synthetic phorboxazole B [83]. 
Highly convergent syntheses of eight phorboxazole congeners and their evaluation against a diverse 
panel of human solid tumor cancer cell lines have been achieved. Specifically, the C(45–46) alkyne, 
alkene,  and  alkane  phorboxazole  A  analogs  were  constructed  and  found  to  display  single  digit 
nanomolar cell growth inhibitory activities in a series of human cancer cell lines. The structurally 
simplified C(11–15)-acetal congener also proved potent, albeit reduced, when evaluated against the 
same  cell  line  panel.  Importantly,  (+)-C(46)-chlorophorboxazole  A  displayed  picomolar  (pM) 
inhibitory activity in several cell lines [84]. 
A  highly  convergent  second-generation  synthesis  of  (+)-phorboxazole  A  (75),  Figure  38,  was 
achieved. Highlights of the synthetic strategy include improved Petasis-Ferrier union/rearrangement 
conditions  on  a  scale  to  assemble  multigram  quantities  of  the  C(11–15)  and  C(22–26) 
cis-tetrahydropyrans inscribed with the phorboxazole architecture, a convenient method to prepare E 
and Z-vinyl bromides from TMS-protected alkynes utilizing radical isomerization of Z-vinylsilanes, 
and a convergent late-stage Stille union to couple a fully elaborated C(1–28) macrocyclic iodide with a Mar. Drugs 2010, 8                                                  
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C(29–46) oxazole stannane side chain, to establish the complete phorboxazole skeleton. The synthesis, 
achieved with a longest linear sequence of 24 steps, resulted in 4.6% overall yield [85]. 
Figure 38. Structure of phorboxazoles. 
  
8. Synthesis of Oxazolines of Marine Origin and Analogues  
The synthesis of westiellamide analogues of type 76, Figure 39, wherein the oxazoline units were 
replaced  by  oxazole  or  thiazole  units,  was  reported  [86].  The  strategy  involved  a  one-pot 
macrocyclization  of  the  monomer  building  blocks  using  diphenyl  phosphorazidate  (DPPA)  in  the 
presence of an excess of Hünig’s base under high dilution conditions at room temperature. The trimers 
76 where X = O or S were obtained in 35% and 25% yield, respectively. The structures of these 
analogues, and also of an imidazole-based analogue, were investigated using X-ray diffraction and 
DFT-based molecular modeling calculations. The flexibility of the systems essentially depends on the 
type of the azole building block. The oxazole-based peptide is almost coplanar, whereas in the case of 
the thiazole and the imidazole cyclicpeptides the azole moieties form cone-like structures. Then, the 
copper(II) coordination chemistry of westiellamide, as well as of the three synthetic analogues (76) 
with an [18]azacrown-6 macrocyclic structure was reported [87]. The authors emphasized that, as in 
the  larger  patellamide  rings,  the  N-heterocycle-N-peptide-N-heterocycle  binding  site  is  highly 
preorganized for copper(II) coordination. The macrocyclic peptides have been found to form stable 
mono- and dinuclear copper(II) complexes. 
Figure 39. Westiellamide analogs and monomers building blocks. 
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